GGrantIndex
← Leaderboards

Steven J Skates

Children'S Hosp Of Philadelphia

$12,789,005
Attributed
$21,457,421
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,019,398 · 13

By mechanism

U01$12,089,317 · 3
R01$4,714,316 · 2
U2C$4,549,053 · 5
P50$2,666,712 · 3

Top collaborators

Most similar at Children'S Hosp Of Philadelphia

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasm Of Ovary

Research focus

Malignant Neoplasm Of OvaryScreening For Ovarian CancerBiological MarkersMalignant NeoplasmsProteomicsWomanSamplingDetectionEarly DiagnosisCohortScreeningCancer BiomarkersValidationSpecificityMortalityOvarianPlasmaProteinsProgramsHigh Risk WomanSignal TransductionProbabilityProtein BiomarkersPerformance

Grant awards (43)

Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer$952,713
U2C · FY2025 · CA · contact PI
Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis$837,856
R01 · FY2025 · CA
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls$693,443
U01 · FY2025 · CA · contact PI
Biomarker Developmental Laboratory (BDL)$387,766
U2C · FY2025 · CA · contact PI
Administrative Core$375,116
U2C · FY2025 · CA · contact PI
Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis$804,864
R01 · FY2024 · CA
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls$390,494
U01 · FY2024 · CA · contact PI
Biostatistics Core$242,718
P50 · FY2024 · CA · contact PI
Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer$922,892
U2C · FY2023 · CA · contact PI
Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis$647,582
R01 · FY2023 · CA
Biomarker Developmental Laboratory (BDL)$414,309
U2C · FY2023 · CA · contact PI
Administrative Core$324,510
U2C · FY2023 · CA · contact PI
Biostatistics Core$293,180
P50 · FY2023 · CA · contact PI
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls$119,967
U01 · FY2023 · CA · contact PI
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood$947,748
U01 · FY2022 · CA
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$747,097
R01 · FY2022 · CA
Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer$686,372
U2C · FY2022 · CA · contact PI
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls$524,401
U01 · FY2022 · CA · contact PI
Biomarker Developmental Laboratory (BDL)$402,579
U2C · FY2022 · CA · contact PI
Biostatistics Core$237,025
P50 · FY2022 · CA · contact PI
Administrative Core$82,796
U2C · FY2022 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$777,101
R01 · FY2021 · CA
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls$546,231
U01 · FY2021 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$400,199
U01 · FY2021 · CA · contact PI
Biostatistics Core$295,240
P50 · FY2021 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$82,995
U01 · FY2021 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$899,816
R01 · FY2020 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$571,713
U01 · FY2020 · CA · contact PI
Biostatistics Core$261,981
P50 · FY2020 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$594,149
U01 · FY2019 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$1,323,251
U01 · FY2018 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$1,356,082
U01 · FY2017 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$829,757
U01 · FY2016 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$902,673
U01 · FY2014 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$672,847
U01 · FY2013 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$701,365
U01 · FY2012 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$720,550
U01 · FY2011 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$711,452
U01 · FY2010 · CA · contact PI
Identifying Novel Serum, Plasma, and Urine Biomarkers of Occult Ovarian Cancer$261,414
P50 · FY2008 · CA · contact PI
Identifying Novel Serum, Plasma, and Urine Biomarkers of Occult Ovarian Cancer$360,795
P50 · FY2007 · CA · contact PI
Novel Serum, Plasma, and Urine Biomarkers of Ovarian Can$238,079
P50 · FY2006 · CA · contact PI
Novel Serum, Plasma, and Urine Biomarkers of Ovarian Can$240,174
P50 · FY2005 · CA
Novel Serum, Plasma, and Urine Biomarkers of Ovarian Can$236,106
P50 · FY2004 · CA